Tenderwize
Wróć do wyszukiwania

Open-House Biologics Discount Agreements 2026-05 - Pegfilgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 29, 2028 · 613 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated contract value or framework maximum value is disclosed. Potential revenue is unknown.

The procedure is not a public procurement under EU directives; legal recourse is via social courts, not procurement tri...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply of Pegfilgrastim pharmaceutical products under discount agreements.
  • Nationwide coverage in Germany.
Pokaż pełne podsumowanie

Open-House procedure for pharmaceutical discount agreements (Rabattverträge) for the active substance Pegfilgrastim, conducted by Techniker Krankenkasse (lead buyer) together with HEK and hkk. The procedure is open to all eligible pharmaceutical entrepreneurs at any time during the contract period. No estimated value, no award criteria, and no procurement documents were analyzed. The contract duration is 24 months from May 2026 to April 2028.

Ryzyka

No estimated contract value or framework maximum value is disclosed. Potential revenue is unknown.

The procedure is not a public procurement under EU directives; legal recourse is via social courts, not procurement tri...

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur according to § 4 Abs. 18 AMG for the offered medicines.
  • Must have a valid marketing authorization for the medicine(s) in Germany or equivalent.

Administrative

  • Must submit a self-declaration on authorization and company (Anlage 4 zum Vertrag).

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House Biologics Discount Agreements 2026-05 - Pegfilgrastim

Conclusion of pharmaceutical discount agreements according to § 130a Abs. 8 SGB V for Pegfilgrastim via an open-house procedure. All eligible pharmaceutical entrepreneurs can join at any time during the contract period. No exclusivity is granted.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Apr 2026 - Apr 2028

Kategoria

Pharmaceutical products

Termin

Deadline Apr 29, 2028

Szczegóły zamówienia

Data publikacji
18 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
190019-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3